FindTrial
Sign In

Prospective, randomized, and controlled trial of IA and HAD regimens in the treatment of newly diagnosed acute myeloid leukemia in multicenter clinical study

Prospective, randomized, and controlled trial of IA and HAD regimens in the treatment of newly diagnosed acute myeloid leukemia in multicenter clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041726
Enrollment
Unknown
Registered
2021-01-03
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Group A:HDA scheme
Group B:IA scheme

Sponsors

Shanxi Bethune Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Age: >= 18 years old and <= 60 years old, male or female; 2) The diagnosis of newly diagnosed acute myeloid leukemia (AML) patients confirmed by morphology, immunology and genetics of bone marrow cells should refer to the WHO standard. 3) ECOG-ps score was 0-2.

Exclusion criteria

Exclusion criteria: 1) With cerebral hemorrhage; 2) Pregnancy; 3) Suffering from mental illness or other conditions can not be carried out according to the plan; 4) Severe arrhythmia, abnormal ECG (QT > 500ms); 5) No informed consent.

Design outcomes

Primary

MeasureTime frame
Complete remission rate;—

Secondary

MeasureTime frame
relapse rate;Treatment related mortality;Event free survival;Overall survival;—

Countries

China

Contacts

Public ContactTao Wang

Shanxi Bethune Hospital of Shanxi Medical University

wangtao99699@163.com+86 13835175119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026